Yu Yafang, Yan Jianwen
Otolaryngology Department, Fujian Medical University Union Hospital, Fuzhou, China.
Fuzhou Second Hospital, Fuzhou, China.
Eur J Med Res. 2024 Dec 19;29(1):607. doi: 10.1186/s40001-024-02210-x.
This study endeavors to comprehensively assess the efficacy of a multimodal therapy protocol in the management and treatment of allergic rhinitis.
This study employed a randomized controlled trial design, enrolling a total of 100 patients, who were randomly assigned to either the experimental group (receiving multimodal therapy) or the control group (receiving standard treatment), with 50 patients in each group. All enrolled patients were diagnosed based on standard guidelines for allergic rhinitis. Standardized AR questionnaires were used to assess patients' symptoms. The primary outcome measures included the time of nasal allergy symptom relief and treatment effectiveness. Statistical software will be utilized for data analysis.
The experimental group showed shorter relief times for symptoms such as nasal itching, nasal congestion, rhinorrhea, and sneezing compared to the control group. Specifically, the relief times for nasal itching, nasal congestion, rhinorrhea, and sneezing in the experimental group were (3.16 ± 0.45) days, (2.68 ± 0.55) days, (2.51 ± 0.23) days, and (3.41 ± 0.31) days, respectively, while the control group's respective times were (5.13 ± 0.77) days, (4.35 ± 0.71) days, (4.85 ± 0.63) days, and (6.73 ± 0.99) days (P < 0.05). After treatment, the total effective rate in the experimental group reached 90.0%, significantly higher than the 66.0% in the control group (P < 0.05).
The results of this study indicate that multimodal therapy not only exhibits significant effectiveness in the management of allergic rhinitis but also holds potential advantages in improving patients' quality of life. These findings provide a new perspective for the treatment of AR and may have significant implications for the design and optimization of future AR treatment regimens.
本研究旨在全面评估多模式治疗方案在变应性鼻炎管理和治疗中的疗效。
本研究采用随机对照试验设计，共纳入100例患者，将其随机分为试验组（接受多模式治疗）和对照组（接受标准治疗），每组50例。所有纳入患者均根据变应性鼻炎的标准指南进行诊断。使用标准化的变应性鼻炎问卷评估患者症状。主要结局指标包括鼻过敏症状缓解时间和治疗效果。将使用统计软件进行数据分析。
与对照组相比，试验组鼻痒、鼻塞、流涕和打喷嚏等症状的缓解时间更短。具体而言，试验组鼻痒、鼻塞、流涕和打喷嚏的缓解时间分别为(3.16±0.45)天、(2.68±0.55)天、(2.51±0.23)天和(3.41±0.31)天，而对照组的相应时间分别为(5.13±0.77)天、(4.35±0.71)天、(4.85±0.63)天和(6.73±0.99)天（P<0.05）。治疗后，试验组的总有效率达到90.0%，显著高于对照组的66.0%（P<0.05）。
本研究结果表明，多模式治疗不仅在变应性鼻炎的管理中显示出显著疗效，而且在改善患者生活质量方面可能具有潜在优势。这些发现为变应性鼻炎的治疗提供了新的视角，可能对未来变应性鼻炎治疗方案的设计和优化具有重要意义。
